Extraction Business Adds to KALY Pharma
Business and PURA and USMJ Partnerships
DALLAS, June 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALYâ€) plans to expand its CBD extraction business to $20 million in 2019 sales. KALY recently announced a contract with a New York State Licensed Hemp Cultivation Operation anticipated to generate an estimated $5 million in revenue for KALY. Today, based on an NBC News Report, KALY’s hemp derived CBD extraction business seems more than ever to be on point in the State of New York. The report highlights a major farming movement in New York toward hemp cultivation. Management is remaining open to the potential of raising its 2019 $20 million CBD extraction target.
See KALY’s full plan to expand its extraction
business to $20 million in sales:
Kali-Extracts
Mobile Cannabis Extraction Capacity
KALY Pharma Business and PURA and USMJ Partnerships
KALY is primarily a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from a proprietary cannabinoid product platform in a
broad range of disease areas. In the fourth quarter of last year,
2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of
operations, the company has established a leading position in the
development of plant-derived cannabinoid therapeutics through a
proven drug discovery and patented development process. The
resulting intellectual property portfolio and the established
regulatory and manufacturing expertise have created a significant
opportunity. KALY has a deep pipeline of cannabinoid product
candidates including four distinct compounds. KALY has
completed the first stage of clinical development and testing for a
Chronic Obstructive Pulmonary Disease (COPD) therapy and is
currently conducting phase one development and trials for compounds
targeting Cancer Pain Management, Type 2 Diabetes and
Epilepsy.
KALY is not relying on its biopharmaceutical development strategy
alone to insure the company’s long-term success. With the
popularity of cannabis extracts for infusion into various consumer
products, KALY’s patented extraction process offers arguably the
highest quality extract to the infusion market. Drawing on
KALY’s patented cannabis extraction expertise, in addition to
winning the $5 million extraction contract mentioned above, KALY
has partnered with Puration, Inc. (PURA) to
lend its extraction expertise in the production of EVERx CBD Sports
Water, the leading CBD infused beverage for the sports nutrition
market. KALY has also introduced its own CBD confections
line, Hemp4mula with CBD infused gum already on the market and
gummies on the way. Hemp4mula is available on the Ecommerce
site USMJ.com hosted by North American Cannabis Holdings, Inc. aka
USMJ (USMJ). KALY’s non-pharmaceutical
extraction revenue strategy offers a business line that can stand
alone, and at the same time provide KALY with the long-term staying
power to bring its cannabis extract biopharmaceutical products to
market.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459